Sector News

Lilly announces Joshua Smiley, Anat Ashkenazi appointments

August 10, 2016
Life sciences

Eli Lilly and Company today announced Joshua Smiley will be appointed to senior vice president, Finance, and treasurer effective October 1. Smiley will replace Thomas Grein, who will retire in September after a 41-year career at Lilly.

Smiley currently serves as senior vice president, Finance, and controller and chief financial officer for Lilly Research Laboratories (LRL). He will report to Derica Rice, executive vice president, Global Services, and chief financial officer.

Succeeding Smiley will be Anat Ashkenazi, vice president, Finance, and chief financial officer for Lilly Manufacturing, Global Quality and Lilly Diabetes.

Grein has been “a steadfast pillar of leadership in our financial organization,” said Rice, explaining that he helped navigate the company in periods of both financial prosperity and uncertainty, including a recent challenging period of patent expirations to a new era of growth.

“With Tom’s guidance, we maintained a strong balance sheet and cash flow that enabled us to make acquisitions and sustain our dividend commitment to Lilly shareholders, even when times were tough,” Rice said.

Having worked with Grein and others to craft and execute aspects of Lilly’s financial strategy, Smiley is extremely well prepared for his new role, Rice said. “Josh’s knowledge and skill helped to place Lilly in a position of strength,” he said. “Josh is a strong analytical and strategic thinker who excels at distilling complex business matters into clear thoughts and actions.”

Smiley has been with Lilly 21 years, serving in a variety of financial, marketing and Six Sigma roles. He has been in his current role since 2011 and before that was vice president, Finance, and chief financial officer for LRL and Lilly Oncology. Smiley is also a member of the board of trustees at Butler University where he serves as treasurer, as well as a member of the board and executive committee for the Indiana Chamber of Commerce.

Ashkenazi joined Lilly 15 years ago. Her career has focused on finance, corporate strategy, business development and Six Sigma. Before assuming her current role she was senior director, Finance, and chief financial officer for Lilly Oncology.

Rice praised Ashkenazi for her strategic thinking, “Anat has a very effective ability to apply strategy into practical solutions. Her exposure to many parts of our organization – including R&D, manufacturing and commercial – combined with her learning agility, energy and commitment, position Anat well for her new role,” he said.

Source: Eli Lilly and Company

comments closed

Related News

December 10, 2023

Brain waves found in sleep shown to protect against epileptic activity

Life sciences

Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.

December 10, 2023

Rousselot’s soft gel capsule stabilizing technology awarded USPTO patent

Life sciences

StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.

December 10, 2023

Roche to acquire obesity drug maker Carmot

Life sciences

In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

How can we help you?

We're easy to reach